Dr. Farhat Afrin

Dr. Farhat Afrin

Associate Professor, Centre for Interdisciplinary Sciences, JISIASR

M.Sc. (Biotechnology, Aligarh Muslim University)
Ph.D. (Jadavpur University)
Post-Doc (NIAID, National Institutes of Health, Bethesda, MD, USA; and
Centre for Immunology and Infection, The Hull York Medical School,
University of York, U.K.)

Email: afrin@jisiasr.org
Google Scholar: https://scholar.google.com/citations?user=SwSWeiYAAAAJ
URLs: https://orcid.org/0000-0003-4443-4284
https://www.scopus.com/authid/detail.uri?authorId=6602621730
https://scholar.google.com/citations?user=SwSWeiYAAAAJ
https://www.linkedin.com/in/farhat-afrin-2b345870/
https://www.researchgate.net/profile/Farhat-Afrin
Researcher ID (Web of Science): F-2346-2018
Author ID (Scopus): 6602621730
ORCID ID: 0000-0003-4443-4284
Loop profile: 119563

Postdoctorate (2002-2003): NIAID, National Institutes of Health, Bethesda, MD, USA;
Postdoctorate: (2010) Centre for Immunology and Infection, The Hull York Medical School,
University of York, UK
Ph.D. (1994-1999) Indian Institute of Chemical Biology, Kolkata, West Bengal, India
M.Sc. (1991-1993) Interdisciplinary Biotechnology Unit, Aligarh Muslim University,
Aligarh, U.P., India

Professional Engagements:
2014-2019: Assistant Professor, Department of Medical Laboratory Technology, Faculty of
Applied Medical Sciences, Taibah University, Madina, Saudi Arabia

2006-2014: Assistant Professor, Department of Biotechnology, Jamia Hamdard (Hamdard
University), New Delhi, India
2003-2005: Lecturer (Sr. scale), Department of Biotechnology, Hamdard University, New
Delhi, India
1999-2003: Lecturer, Department of Biotechnology, Hamdard University, New Delhi, India
1998-1999: Lecturer (Adhoc), Department of Biotechnology, Hamdard University, New
Delhi, India

Research Topic:
Our research encompasses vaccinology and immunology of infectious diseases, and
nanomedicine. We are currently investigating therapeutic interventions of infectious diseases,
leishmaniasis and cancer using nanoparticles alone or as drug carriers. Dendritic cell and
nano-particles based prophylactic and therapeutic vaccines is also being explored.